|
|
Post by boca1girl on Feb 8, 2019 8:05:47 GMT -5
Last evening I talked to a woman I have known for about 8 years who became a T1 in her late 50’s. I have mentioned Afrezza to her over the last few years and she politely told me thanks but she was not interested in making any changes to her treatment plan. I think the subtle message was that I was not a doctor and I shouldn’t be making such a suggestion. So the last time I mentioned Afrezza to her was over a year ago. After seeing the Dr. Edelman recent video and the “I admit it” video, I couldn’t help but mention Afrezza to her again last night. I asked her if it would be ok for me to send her two short videos, made by doctors, about Afrezza. She said sure but also said that she was reluctant to make any changes. So I sent her both videos last night and this morning I got a note back from her that said they were very interesting and she will ask her doctor about it at her next appointment. But she then said insurance coverage will have a big effect on if she ever tries it. I followed with another note with the links for the cash pay and copay card programs. Maybe I finally got her to seriously consider it. Update to this story. This woman send me a note yesterday explaining what happened at her Endo visit a couple of days ago. Unfortunately, Afrezza was rejected not only for her but all the other pump users at the group visit. ... I'd like to thank you for sending me all the interesting videos and information on Afrezza. I had my appointment with my endo yesterday(shared medical appointment with several other patients) and we discussed Afrezza. My doctor was very up to date on all the info and even gave a brief history on how it has evolved. After a lot of discussion it was decided that because we are on insulin pumps we can have better control of our dosage of insulin and therefore our diabetes and that Afrezza is not for us. I personally believe that and I also don't want to open myself to the possibility of creating new problems say with my lungs. Unfortunately we lost her and the several other patients after this appointment. I wonder if the good Endo really was up to date or had a different agenda. |
|
|
|
Post by dh4mizzou on Feb 8, 2019 8:12:15 GMT -5
You need to talk that person into going rogue and visiting a different endo who will prescribe Afrezza. then after their A1C is reduced by 40%, and their TIR is nearly 100%, they can go back to their "pumping" group and fill them in with the real scoop.
|
|
|
|
Post by boca1girl on Feb 8, 2019 8:15:36 GMT -5
You need to talk that person into going rogue and visiting a different endo who will prescribe Afrezza. then after their A1C is reduced by 40%, and their TIR is nearly 100%, they can go back to their "pumping" group and fill them in with the real scoop. This woman is 70+ and very cautious. Her note politely told me to back off. |
|
|
|
Post by mnholdem on Feb 8, 2019 8:17:11 GMT -5
Unfortunately, this endo is actually up-to-date when s/he states that Afrezza delivers less control than a pump. Why? Because there have been ZERO publications by MannKind in major medical journals to dispute what this endocrinologist has learned about inhaled insulin. The STAT results were published in by Kartish Garg MD in his diabetes journal, which has a smaller readership than Lancet, AMA or NEJM. This lack of current and available medical information is kicking MannKind in the rear end, IMO. For all the money being spent on DTC ads for Afrezza, what good will it do if the doctors refuse to prescribe it? Where are the new publications that Castagna/Kendall stated would soon be released? I believe the statement about upcoming medical publications was made at either the Cantor Fitzgerald Global Healthcare Conference on Oct 2, 2018 or the Rodman & Renshaw 20th Annual Global Investment Conference on Sept 5, 2018.  |
|
|
|
Post by peppy on Feb 8, 2019 8:18:05 GMT -5
Last evening I talked to a woman I have known for about 8 years who became a T1 in her late 50’s. I have mentioned Afrezza to her over the last few years and she politely told me thanks but she was not interested in making any changes to her treatment plan. I think the subtle message was that I was not a doctor and I shouldn’t be making such a suggestion. So the last time I mentioned Afrezza to her was over a year ago. After seeing the Dr. Edelman recent video and the “I admit it” video, I couldn’t help but mention Afrezza to her again last night. I asked her if it would be ok for me to send her two short videos, made by doctors, about Afrezza. She said sure but also said that she was reluctant to make any changes. So I sent her both videos last night and this morning I got a note back from her that said they were very interesting and she will ask her doctor about it at her next appointment. But she then said insurance coverage will have a big effect on if she ever tries it. I followed with another note with the links for the cash pay and copay card programs. Maybe I finally got her to seriously consider it. Update to this story. This woman send me a note yesterday explaining what happened at her Endo visit a couple of days ago. Unfortunately, Afrezza was rejected not only for her but all the other pump users at the group visit. ... I'd like to thank you for sending me all the interesting videos and information on Afrezza. I had my appointment with my endo yesterday(shared medical appointment with several other patients) and we discussed Afrezza. My doctor was very up to date on all the info and even gave a brief history on how it has evolved. After a lot of discussion it was decided that because we are on insulin pumps we can have better control of our dosage of insulin and therefore our diabetes and that Afrezza is not for us. I personally believe that and I also don't want to open myself to the possibility of creating new problems say with my lungs. Unfortunately we lost her and the several other patients after this appointment. I wonder if the good Endo really was up to date or had a different agenda. thank you bocagirl: Now we know. "better control of our dosage of insulin and therefore our diabetes" Let me rewrite that for him. "It s my belief that on a pump I have better control of your dosage of insulin, there fore I have better control of your diabetes." And then we all said, alrighty then. |
|
|
|
Post by sportsrancho on Feb 8, 2019 8:27:57 GMT -5
When there’s enough people using Afrezza and people actually start seeing them out and about in person it’s going to have a huge effect. When you actually see something in person it so much different than reading about it or looking at pictures.
|
|
|
|
Post by careful2invest on Feb 8, 2019 8:29:19 GMT -5
Unfortunately, this endo is actually up-to-date when s/he states that Afrezza delivers less control than a pump. Why? Because there have been ZERO publications by MannKind in major medical journals to dispute what this endocrinologist has learned about inhaled insulin. The STAT results were published in by Kartish Garg MD in his diabetes journal, which has a smaller readership than Lancet, AMA or NEJM. This lack of current and available medical information is kicking MannKind in the rear end, IMO. For all the money being spent on DTC ads for Afrezza, what good will it do if the doctors refuse to prescribe it? Where are the new publications that Castagna/Kendall stated would soon be released. I believe the statement about upcoming medical publications was made at either the Cantor Fitzgerald Global Healthcare Conference on Oct 2, 2018 or the Rodman & Renshaw 20th Annual Global Investment Conference on Sept 5, 2018. I agree. Now that MannKind is putting out so many Afrezza commercials, there needs to be a seamless path to availability. In addition, social media needs to be looked after intensely. It’s go time people! No stone unturned! All cylinders need to be firing simultaneously for ultimate success! No room for any additional mistakes from MNKD management! GLTA LONGS! |
|
|
|
Post by Thundersnow on Feb 8, 2019 8:38:43 GMT -5
That's very common. Endos mentality is if my patient is stable even though their A1C is > 6.0 I will not change their treatment. Unfortunately that's the case and it will take a few years for those Endos to be convinced about the benefits of Afrezza.
|
|
|
|
Post by mnholdem on Feb 8, 2019 8:44:41 GMT -5
Concurrent project management is what's needed rather than sequential, IMO. Typically, the concept is simple but execution can be difficult. To be successful, simultaneous project management for marketing a disruptive product must employ: - early and ongoing release of information;
- effective organizational integration and expectations;
- multi-functional team-based activity.
I think CEO Castagna has pulled some of this in place with his executive team, but there appear to be a few voids, particularly in medical media and social media information channels. I imagine that the CEO is doing his best to put everything in place. Just remember the old adage: "A poor plan will take you 3-5 times longer to execute than you think it will. A good plan will only take twice as long."  |
|
|
|
Post by mnkdfann on Feb 8, 2019 9:04:13 GMT -5
Unfortunately, this endo is actually up-to-date when s/he states that Afrezza delivers less control than a pump. Why? Because there have been ZERO publications by MannKind in major medical journals to dispute what this endocrinologist has learned about inhaled insulin. The STAT results were published in by Kartish Garg MD in his diabetes journal, which has a smaller readership than Lancet, AMA or NEJM. This lack of current and available medical information is kicking MannKind in the rear end, IMO. For all the money being spent on DTC ads for Afrezza, what good will it do if the doctors refuse to prescribe it? Where are the new publications that Castagna/Kendall stated would soon be released? I believe the statement about upcoming medical publications was made at either the Cantor Fitzgerald Global Healthcare Conference on Oct 2, 2018 or the Rodman & Renshaw 20th Annual Global Investment Conference on Sept 5, 2018. Also, at the ASM in May 2018, they promised 16 publications in the months ahead. "Dr. Kendall ... stated that MannKind now has approximately 16 additional publications that will be coming out in the months ahead." mnkd.proboards.com/post/147727 |
|
|
|
Post by agedhippie on Feb 8, 2019 12:00:27 GMT -5
Update to this story. This woman send me a note yesterday explaining what happened at her Endo visit a couple of days ago. Unfortunately, Afrezza was rejected not only for her but all the other pump users at the group visit. ... I'd like to thank you for sending me all the interesting videos and information on Afrezza. I had my appointment with my endo yesterday(shared medical appointment with several other patients) and we discussed Afrezza. My doctor was very up to date on all the info and even gave a brief history on how it has evolved. After a lot of discussion it was decided that because we are on insulin pumps we can have better control of our dosage of insulin and therefore our diabetes and that Afrezza is not for us. I personally believe that and I also don't want to open myself to the possibility of creating new problems say with my lungs. Unfortunately we lost her and the several other patients after this appointment. I wonder if the good Endo really was up to date or had a different agenda. It was unfortunate that it was a group rather than 1:1 because then there are going to be other group members arguing for the pump. I am quite impressed that the endo is sufficiently engaged to hold group meetings like that. I am not going to criticize the endo at all, the official data supports the endo's position. Until there are properly staged trials this will keep happening. |
|
|
|
Post by peppy on Feb 8, 2019 12:10:33 GMT -5
Update to this story. This woman send me a note yesterday explaining what happened at her Endo visit a couple of days ago. Unfortunately, Afrezza was rejected not only for her but all the other pump users at the group visit. ... I'd like to thank you for sending me all the interesting videos and information on Afrezza. I had my appointment with my endo yesterday(shared medical appointment with several other patients) and we discussed Afrezza. My doctor was very up to date on all the info and even gave a brief history on how it has evolved. After a lot of discussion it was decided that because we are on insulin pumps we can have better control of our dosage of insulin and therefore our diabetes and that Afrezza is not for us. I personally believe that and I also don't want to open myself to the possibility of creating new problems say with my lungs. Unfortunately we lost her and the several other patients after this appointment. I wonder if the good Endo really was up to date or had a different agenda. It was unfortunate that it was a group rather than 1:1 because then there are going to be other group members arguing for the pump. I am quite impressed that the endo is sufficiently engaged to hold group meetings like that. I am not going to criticize the endo at all, the official data supports the endo's position. Until there are properly staged trials this will keep happening. 70 year olds. |
|
|
|
Post by mannmade on Feb 8, 2019 12:24:53 GMT -5
Yes what is mnkd doing to target it’s message to mellenials and pwd in their late teens, early 20’s to 30’s. They are the tech savvy new adopters! Not sure they are watching CNN, Fox et al... this is where they should run ads on college campus networks, and fb, social media etc...
|
|
|
|
Post by radgray68 on Feb 8, 2019 12:25:12 GMT -5
I've asked the diabetics in my clinic about their treatments for years and the overwhelming response is something akin to the adage: Better the devil you know...
That attitude leads me to believe resistance to change is our main roadblock going forward. Doctors too. However, pediatric patients and newly diagnosed T2's don't have that super strong treatment loyalty yet. I firmly believe if a patient starts and has success on inhaled insulin, needles will seem barbaric. JMHO
|
|
|
|
Post by sportsrancho on Feb 8, 2019 15:44:12 GMT -5
Shush ....don’t tell anybody, word is spreading:-) Hot- topic within in six months..Afrezza😉💥
|
|
